SK1082003A3 - Particulate composition of eletriptane - Google Patents

Particulate composition of eletriptane Download PDF

Info

Publication number
SK1082003A3
SK1082003A3 SK108-2003A SK1082003A SK1082003A3 SK 1082003 A3 SK1082003 A3 SK 1082003A3 SK 1082003 A SK1082003 A SK 1082003A SK 1082003 A3 SK1082003 A3 SK 1082003A3
Authority
SK
Slovakia
Prior art keywords
pharmaceutical composition
eletriptan
composition according
core
pharmaceutically acceptable
Prior art date
Application number
SK108-2003A
Other languages
English (en)
Slovak (sk)
Inventor
Raspide Manaud Pierre Frede De
Ross James Macrae
Mathias Walther
Original Assignee
Pfizer
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer filed Critical Pfizer
Publication of SK1082003A3 publication Critical patent/SK1082003A3/sk

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5073—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings
    • A61K9/5078—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings with drug-free core
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005—Wall or coating material
    • A61K9/5021—Organic macromolecular compounds
    • A61K9/5026—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5084—Mixtures of one or more drugs in different galenical forms, at least one of which being granules, microcapsules or (coated) microparticles according to A61K9/16 or A61K9/50, e.g. for obtaining a specific release pattern or for combining different drugs

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Pain & Pain Management (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Electroluminescent Light Sources (AREA)
  • Luminescent Compositions (AREA)
SK108-2003A 2000-08-02 2001-07-18 Particulate composition of eletriptane SK1082003A3 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB0018968.8A GB0018968D0 (en) 2000-08-02 2000-08-02 Particulate composition
PCT/IB2001/001279 WO2002009675A1 (en) 2000-08-02 2001-07-18 Particulate composition of eletriptan showing a sigmoidal pattern of controlled release

Publications (1)

Publication Number Publication Date
SK1082003A3 true SK1082003A3 (en) 2004-09-08

Family

ID=9896843

Family Applications (1)

Application Number Title Priority Date Filing Date
SK108-2003A SK1082003A3 (en) 2000-08-02 2001-07-18 Particulate composition of eletriptane

Country Status (39)

Country Link
US (1) US20020034545A1 (pl)
EP (1) EP1365748B1 (pl)
JP (1) JP2004505034A (pl)
KR (1) KR20030024820A (pl)
CN (1) CN1630511A (pl)
AP (1) AP2001002233A0 (pl)
AR (1) AR030099A1 (pl)
AT (1) ATE308978T1 (pl)
AU (1) AU2001270932A1 (pl)
BG (1) BG107361A (pl)
BR (1) BR0112839A (pl)
CA (1) CA2417887C (pl)
CZ (1) CZ2003241A3 (pl)
DE (1) DE60114887T2 (pl)
EA (1) EA200300110A1 (pl)
EC (1) ECSP034451A (pl)
EE (1) EE200300051A (pl)
ES (1) ES2250429T3 (pl)
GB (1) GB0018968D0 (pl)
GT (1) GT200100149A (pl)
HR (1) HRP20030036A2 (pl)
HU (1) HUP0301453A2 (pl)
IL (1) IL153494A0 (pl)
IS (1) IS6649A (pl)
MA (1) MA26934A1 (pl)
MX (1) MXPA03000999A (pl)
NO (1) NO20030498D0 (pl)
NZ (1) NZ522976A (pl)
OA (1) OA12348A (pl)
PA (1) PA8523101A1 (pl)
PE (1) PE20020385A1 (pl)
PL (1) PL359847A1 (pl)
PY (1) PY0117547A (pl)
SK (1) SK1082003A3 (pl)
SV (1) SV2002000574A (pl)
TN (1) TNSN01115A1 (pl)
UY (1) UY26861A1 (pl)
WO (1) WO2002009675A1 (pl)
ZA (1) ZA200300868B (pl)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040022853A1 (en) * 2001-04-26 2004-02-05 Control Delivery Systems, Inc. Polymer-based, sustained release drug delivery system
AU2003294520A1 (en) * 2002-12-16 2004-07-09 Chx Technologies, Inc. Temporary, pharmacologically-inactive dental coating for the in situ protection of dental therapeutic agents from saliva and abrasion from chewing
WO2004089365A1 (en) 2003-04-11 2004-10-21 Pfizer Limited Pharmaceutical combination comprising eletriptan and sodium bicarbonate
GB2407498B (en) * 2003-10-30 2008-06-11 Cipla Ltd Oral formulations for 5-HT receptor agonists with reduced degradation of active ingredient
WO2005120456A2 (en) * 2004-06-09 2005-12-22 Pfizer Limited Formulation of eletriptan
WO2006013431A1 (en) * 2004-07-29 2006-02-09 Pfizer Limited Stable controlled-release pharmaceutical formulation of eletriptan
WO2006080481A1 (ja) * 2005-01-31 2006-08-03 Kyorin Pharmaceutical Co., Ltd. マルチプルユニット型経口徐放性製剤及びその製造方法
US11311490B2 (en) 2005-08-10 2022-04-26 Add Advanced Drug Delivery Technologies Ltd. Oral preparation with controlled release
US20070134322A1 (en) * 2005-12-14 2007-06-14 Forest Laboratories, Inc. Modified and pulsatile release pharmaceutical formulations of escitalopram
ES2396051T3 (es) * 2006-04-26 2013-02-18 Supernus Pharmaceuticals, Inc. Preparaciones de liberación controlada de oxcarbazepina que tienen perfil de liberación sigmoidal
WO2008115797A1 (en) * 2007-03-16 2008-09-25 Pavo, Inc. Therapeutic compositions and methods
CA2694440A1 (en) 2007-07-25 2009-01-29 Biolex Therapeutics, Inc. Controlled release interferon drug products and treatment of hcv infection using same
KR20120110098A (ko) 2009-11-16 2012-10-09 에보니크 룀 게엠베하 고형 (메트)아크릴레이트 공중합체를 분산제에 의해 분산된 형태로 전환시키는 방법
BR112017004552A2 (pt) * 2014-09-09 2017-12-05 Charleston Laboratories Inc composições farmacêuticas
GB201716716D0 (en) * 2017-10-12 2017-11-29 Univ Of Hertfordshire Higher Education Corporation Method for coating particles

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2624732B1 (fr) * 1987-12-21 1991-02-15 Synthelabo Formulation pharmaceutique a liberation prolongee
US5411745A (en) * 1994-05-25 1995-05-02 Euro-Celtique, S.A. Powder-layered morphine sulfate formulations
GB9417310D0 (en) * 1994-08-27 1994-10-19 Pfizer Ltd Therapeutic agents
GB9825988D0 (en) * 1998-11-27 1999-01-20 Pfizer Ltd Indole derivatives
GB9922963D0 (en) * 1999-09-28 1999-12-01 Pfizer Ltd Polymorphic salt
FR2795962B1 (fr) * 1999-07-08 2003-05-09 Prographarm Laboratoires Procede de fabrication de granules enrobes a gout masque et liberation immediate du principe actif
US20020044962A1 (en) * 2000-06-06 2002-04-18 Cherukuri S. Rao Encapsulation products for controlled or extended release

Also Published As

Publication number Publication date
TNSN01115A1 (fr) 2005-11-10
OA12348A (en) 2004-03-19
EP1365748B1 (en) 2005-11-09
GT200100149A (es) 2002-06-25
KR20030024820A (ko) 2003-03-26
NO20030498L (no) 2003-01-31
DE60114887D1 (de) 2005-12-15
PY0117547A (es) 2003-11-03
PA8523101A1 (es) 2002-08-26
DE60114887T2 (de) 2006-07-20
SV2002000574A (es) 2002-12-02
HUP0301453A2 (hu) 2003-08-28
AP2001002233A0 (en) 2001-09-30
BG107361A (bg) 2003-06-30
EE200300051A (et) 2004-10-15
NZ522976A (en) 2004-11-26
ECSP034451A (es) 2003-03-10
ES2250429T3 (es) 2006-04-16
ZA200300868B (en) 2004-04-16
MXPA03000999A (es) 2003-06-09
HRP20030036A2 (en) 2003-04-30
CA2417887A1 (en) 2002-02-07
BR0112839A (pt) 2003-06-24
CN1630511A (zh) 2005-06-22
AU2001270932A1 (en) 2002-02-13
CA2417887C (en) 2006-11-14
WO2002009675A9 (en) 2003-09-18
WO2002009675A1 (en) 2002-02-07
UY26861A1 (es) 2002-02-28
IL153494A0 (en) 2003-07-06
JP2004505034A (ja) 2004-02-19
AR030099A1 (es) 2003-08-13
PE20020385A1 (es) 2002-05-11
IS6649A (is) 2002-12-05
GB0018968D0 (en) 2000-09-20
EP1365748A2 (en) 2003-12-03
ATE308978T1 (de) 2005-11-15
EA200300110A1 (ru) 2003-06-26
NO20030498D0 (no) 2003-01-31
CZ2003241A3 (cs) 2004-02-18
MA26934A1 (fr) 2004-12-20
PL359847A1 (pl) 2004-09-06
US20020034545A1 (en) 2002-03-21

Similar Documents

Publication Publication Date Title
US7314640B2 (en) Formulation and process for drug loaded cores
JP2002532425A (ja) 新規な医薬製剤
JP2002523443A (ja) オメプラゾール製剤
EP1919473B1 (fr) Association d'un agent hypnotique a duree d'action longue et d'un agent hypnotique a duree d'action courte et son application therapeutique
KR20100126465A (ko) 미코페놀레이트를 포함하는 변형 방출 제약 조성물 및 그것의 방법
JP2006522099A (ja) 複合粒状体からなる経口徐放性圧縮錠
EP2275139A1 (en) Oral pharmaceutical dosage forms comprising a proton pump inhibitor and a NSAID
RS77904A (sr) Oblik za oralnu primenu teško rastvornih baznih delotvornih supstanci
JP2001511443A (ja) 抗潰瘍活性化合物を含んでなる経口医薬製剤およびその製造方法
PL210862B1 (pl) Kompozycja farmaceutyczna w postaci peletki do doustnego podawania i sposób wytwarzania kompozycji
CA2417887C (en) Particulate composition of eletriptan
US20130216617A1 (en) Pharmaceutical compositions of (r)-lansoprazole
EP2034974A2 (en) Lipoic acid pellets
WO2009002416A1 (en) Controlled release tamsulosin hydrochloride formulation
JP2001500150A (ja) ［Ｒ―（Ｚ）］―α―（メトキシイミノ）―α―（１―アザビシクロ［２．２．２］オクト―３―イル）アセトニトリル一塩酸塩の制御放出投与形態
EP0393747A2 (en) Mebeverine dosage form
US20110244033A1 (en) Tamsulosin pellets for fixed dose combination
KR20100130882A (ko) 서방성 비스테로이드성 소염제 조성물 및 그 제조방법
CN101208078A (zh) 基于质子泵抑制剂的口服药剂
CA2547586C (en) Controlled-release pharmaceutical formulation
WO2005051362A2 (en) Oral benzimidazole compositions comprising an active core, an optional separating layer and an enteric coating
CN101132782A (zh) 氯沙坦的口服药物剂型
MXPA00008985A (en) Solid oral pharmaceutical formulation of modified release that contains an acid labile benzimidazole compound
HK1001761B (en) Oral pharmaceutical dosage forms comprising a proton pump inhibitor and a nsaid
HK1152887A (en) Oral pharmaceutical dosage forms comprising a proton pump inhibitor and a nsaid

Legal Events

Date Code Title Description
FC9A Refused patent application